Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity

References

• Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 31, 803–805 (2000).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 36, S69–S78 (2003).
   PubMed Web of Science ®Google Scholar
• Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 16, 375–388 (2002).
   PubMed Web of Science ®Google Scholar
• Kotler D. Challenges to diagnosis of HIV-associated wasting. J. Acquir. Immune Defic. Syndr. 37, S280–S283 (2004).
   Google Scholar
• Parker KL, Schimmer BP. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds). McGraw Hill, NY, USA, 1541–1549 (2001).
   Google Scholar
• Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog. Horm. Res. 52, 215–244 (1997).
   PubMedGoogle Scholar
• Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999).
   PubMed Web of Science ®Google Scholar
• Recombinant human growth hormone. Medical Letter Drugs Therapy 32, 77–78 (1992).
   Google Scholar
• Heck AM, Calis KA, Yanovski JA. Pharmacotherapy: A Pathophysiologic Approach. Dipiro JT (Ed.). McGraw Hill, NY, USA, 1288–1291 (1999).
   Google Scholar
• de Boer H, van der Veen E. Guidelines for optimizing growth hormone replacement therapy in adults. Horm. Res. 48(Suppl. 5), 21–30 (1997).
   PubMedGoogle Scholar
• Drake WM, Coyte D, Camacho-Hubner C et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83, 3913–3919 (1998).
   PubMed Web of Science ®Google Scholar
• Voerman HJ, Strack van Schijndel RJ, de Boer H, van der Veen EA, Thijs LG. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Neth. J. Med. 41, 229–244 (1992).
   PubMed Web of Science ®Google Scholar
• Koea JB, Breier BH, Douglas RG, Gluckman PD, Shaw JH. Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis. Br. J. Surg. 83, 196–202 (1996).
   PubMed Web of Science ®Google Scholar
• Carroll PV, Van den Berghe G. Safety aspects of pharmacological GH therapy in adults. Growth Horm. IGF Res. 11, 166–172 (2001).
   PubMed Web of Science ®Google Scholar
• Snel YE, Doerga ME, Brummer RM, Zelissen PM, Koppeschaar HP. Magnetic resonance imaging-assessed adipose tissue and serum lipid and insulin concentrations in growth hormone-deficient adults. Effect of growth hormone replacement. Arterioscler. Thromb. 15, 1543–1548 (1995).
   Google Scholar
• Bengtsson BA, Eden S, Lonn L et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 76, 309–317 (1993).
   PubMed Web of Science ®Google Scholar
• Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu. Rev. Med. 54, 513–533 (2003).
   PubMed Web of Science ®Google Scholar
• Johannsson G, Marin P, Lonn L et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727–734 (1997).
   PubMed Web of Science ®Google Scholar
• Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J, Jorgensen JO. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 266, E211–E216 (1994).
   PubMed Web of Science ®Google Scholar
• Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Homone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382–395 (1998).
   PubMed Web of Science ®Google Scholar
• Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J. Clin. Endocrinol. Metab. 86, 1868–1870 (2001).
   PubMed Web of Science ®Google Scholar
• Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. J. Am. Med. Assoc. 285, 1736–1745 (2001).
   PubMed Web of Science ®Google Scholar
• Juul A, Bernasconi S, Carel JC et al. Growth hormone treatment and risk of solid tumours. A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE). Horm. Res. 60, 103–104 (2003).
   PubMedGoogle Scholar
• Jensen PB, Ekelund B, Nielsen FT, Baumbach L, Pedersen FB, Oxhoj H. Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin. Nephrol. 53, 25–32 (2000).
   PubMed Web of Science ®Google Scholar
• Lee PD, Pivarnik JM, Bukar JG et al. A randomized, placebo-controlled trial of combined insulin-like growth Factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 81, 2968–2975 (1996).
   PubMed Web of Science ®Google Scholar
• Waters D, Danska J, Hardy K et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125, 865–872 (1996).
   PubMed Web of Science ®Google Scholar
• Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785–792 (1999).
   PubMed Web of Science ®Google Scholar
• CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb. Mortal. Wkly Rep. 36, 3–15 (1987).
   PubMedGoogle Scholar
• Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS 15, 411–423 (2001).
   PubMed Web of Science ®Google Scholar
• Wheeler DA, Gibert CL, Launer CA et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J. Acquir. Immune Defic. Syndr. 18, 80–85 (1998).
   Web of Science ®Google Scholar
• Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J. Nutr. 129, 282S–289S (1999).
   Web of Science ®Google Scholar
• Wilson IB, Roubenoff R, Knox TA, Spiegelman D, Gorbach SL. Relation of lean body mass to health-related quality of life in persons with HIV. J. Acquir. Immune Defic. Syndr. 24, 137–146 (2000).
   PubMed Web of Science ®Google Scholar
• Kotler D. Challenges to diagnosis of HIV wasting. J. Acquir. Immune Defic. Syndr. 37, S280–S283 (2004).
   Google Scholar
• Wanke C. Pathogenesis and consequence of HIV wasting. J. Acquir. Immune Defic. Syndr. 37, S277–S279 (2004).
   PubMedGoogle Scholar
• Heijligenberg R, Sauerwein HP, Brabant G, Endert E, Hommes MJ, Romijn JA. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 81, 4028–4032 (1996).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Lee K et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J. Clin. Endocrinol. Metab. 81, 4051–4058 (1996).
   PubMed Web of Science ®Google Scholar
• Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 78, 404–410 (1994).
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 77, 956–962 (1993).
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Koster FT, Crist DM et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J. Acquir. Immune Defic. Syndr. 6, 245–251 (1993).
   PubMed Web of Science ®Google Scholar
• Schambelan M, Mulligan K, Grunfeld C et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann. Intern. Med. 125, 873–882 (1996).
   PubMed Web of Science ®Google Scholar
• Moyle G, Daar E, Gertner J et al. Growth hormone improves lean body mass, physical performance and quality of life in subjects with HIV associated weight loss or wasting on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 35(4), 367–375 (2004).
   Google Scholar
• Tai VW, Schambelan M, Algren H, Shayevich C, Mulligan K. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin. Infect. Dis. 35, 1258–1262 (2002).
   PubMed Web of Science ®Google Scholar
• Mauras N, Horber FF, Haymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J. Clin. Endocrinol. Metab. 75, 1192–1197 (1992).
   PubMed Web of Science ®Google Scholar
• Kuzuya H, Matsuura N, Sakamoto M et al. Trial of insulin like growth Factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42, 696–705 (1993).
   PubMed Web of Science ®Google Scholar
• Mauras N. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J. Clin. Endocrinol. Metab. 80, 2633–2637 (1995).
   PubMed Web of Science ®Google Scholar
• Moyle G, Schoelles K, Farbach K et al. Efficacy of selected treatments of HIV wasting: a systemic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 37, S262–S276 (2004).
   Google Scholar
• Daar E, Gaccione P, Muurahainen N, Kotler D, Landy H. Treatment of AIDS wasting with mammalian cell-derived recombinant human growth hormone (r-hGHm) is associated with improved survival. Fifth International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2000).
   Google Scholar
• Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. ‘Buffalo hump’ in men with HIV-1 infection. Lancet 351, 867–870 (1998).
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51–F58 (1998).
   PubMed Web of Science ®Google Scholar
• Engelson ES, Kotler DP, Tan Y et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am. J. Clin. Nutr. 69, 1162–1169 (1999).
   PubMed Web of Science ®Google Scholar
• Gripshover B, Tien PC, Saag M et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. 10th Conference on Retroviruses and Opportunistic Infections. MA, USA (2003).
   Google Scholar
• Tien PC, Cole SR, Williams CM et al. Incidence of lipoatrophy and lipohypertrophy in the women’s interagency HIV study. J. Acquir. Immune Defic. Syndr. 34, 461–466 (2003).
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 287, 356–359 (2002).
   PubMed Web of Science ®Google Scholar
• Pouliot MC, Despres JP, Nadeau A et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41, 826–834 (1992).
   PubMed Web of Science ®Google Scholar
• Zamboni M, Armellini F, Milani MP et al. Evaluation of regional body fat distribution: comparison between W/H ratio and computed tomography in obese women. J. Intern. Med. 232, 341–347 (1992).
   PubMed Web of Science ®Google Scholar
• Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36, 54–59 (1987).
   PubMed Web of Science ®Google Scholar
• Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese–American men and women with impaired glucose tolerance. Diabetologia 37, 524–532 (1994).
   PubMed Web of Science ®Google Scholar
• Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron. Artery Dis. 9, 473–481 (1998).
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Liem AY, South S et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J. Clin. Endocrinol. Metab. 80, 3209–3222 (1995).
   PubMed Web of Science ®Google Scholar
• Ghigo E, Procopio M, Boffano GM et al. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 41, 560–563 (1992).
   PubMed Web of Science ®Google Scholar
• Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J. Clin. Endocrinol. Metab. 86, 504–510 (2001).
   PubMed Web of Science ®Google Scholar
• Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. 286, E296–E303 (2004).
   PubMedGoogle Scholar
• Lo JC, Mulligan K, Noor MA et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 86, 3480–3487 (2001).
   PubMed Web of Science ®Google Scholar
• Saag M, Powderly WG, Schambelan M. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection. Summary of selected trials. Top. HIV Med. 10, 47–51 (2002).
   Google Scholar
• Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13, 2099–2103 (1999).
   PubMed Web of Science ®Google Scholar
• Torres RA, Unger KW, Cadman JA, Kassous JY. Recombinant human growth hormone improves truncal adiposity and ‘buffalo humps’ in HIV-positive patients on HAART. AIDS 13, 2479–2481 (1999).
   PubMed Web of Science ®Google Scholar
• Engelson ES, Glesby MJ, Mendez D et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J. Acquir. Immune Defic. Syndr. 30, 379–391 (2002).
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Mulligan K, Lee J et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 87, 942 (2002).
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 35, 239–252 (2004).
   PubMed Web of Science ®Google Scholar
• Andersen O, Haugaard SB, Flyvbierg A et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur. J. Clin. Invest. 34, 561–568 (2004).
   PubMed Web of Science ®Google Scholar
• Lo JC, Mulligan K, Noor MA et al. The effects of low dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin. Infect. Dis. 39, 732–735 (2004).
   PubMed Web of Science ®Google Scholar
• Falutz J, Allas S, Kotler D et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 19, 1279–1287 (2005).
   PubMedGoogle Scholar
• Snyder DK, Underwood LE, Clemmons DR. Anabolic effects of growth hormone in obese diet-restricted subjects are dose-dependent. Am. J. Clin. Nutr. 52, 431–437 (1990).
   PubMed Web of Science ®Google Scholar
• Laurence J, Grimison B, Gonenne A. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro. Blood 79, 467–472 (1992).
   PubMed Web of Science ®Google Scholar
• Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. J. Am. Med. Assoc. 292, 210–218 (2004).
   PubMed Web of Science ®Google Scholar
• Murray RD. Adult growth hormone replacement: current understanding. Curr. Opin. Pharm. 3, 642–649 (2003).
   PubMed Web of Science ®Google Scholar
• Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J. Clin. Endocrinol. Metab. 83, 572–580 (1998).
   Google Scholar
• Svensson J, Monson JP, Velter T et al. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin. Endocrinol. 58, 572–580 (2003).
   Google Scholar
• Paton NI, Newton PJ, Sharpstone DR et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 13, 1195–1202 (1999).
   PubMed Web of Science ®Google Scholar
• Bonyhadi ML, Rabin L, Salimi S et al. HIV induces thymus depletion in vivo. Nature 363, 728–732 (1993).
   PubMed Web of Science ®Google Scholar
• Su L, Kaneshima H, Bonyhadi M et al. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 2, 25–36 (1995).
   PubMed Web of Science ®Google Scholar
• McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974–979 (2001).
   PubMed Web of Science ®Google Scholar
• Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16, 1103–1111 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen BY, Clerici M, Venzon DJ et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 12, 895–904 (1998).
   PubMed Web of Science ®Google Scholar
• Jager H, Knechten H, Moll A, Weitner L, Fischer H, Schmitt-Rau K. Treatment of HIV-associated wasting with recombinant human growth hormone: monitoring of body composition changes by bioelectrical impedance analysis (BIA). Eur. J. Med. Res. 7, 103–108 (2002).
   PubMed Web of Science ®Google Scholar
• He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J. Appl. Physiol. 94, 2051–2057 (2003).
   PubMed Web of Science ®Google Scholar